Financial Performance Summary

Aurobindo Pharma Limited reported unaudited consolidated financial results for Q1 FY27 ended June 30, 2026.

Key Financial Metrics:

| Metric | Q1FY27 | Q1FY26 | YoY Change | Q4FY26 | QoQ Change |

| Revenue from Operations (₹ Cr) | 9,150 | 7,868 | +16.3% | 8,853 | +3.4% |

| EBITDA before R&D (₹ Cr) | 2,208 | 1,947 | +13.4% | 2,165 | +2.0% |

| EBITDA margin before R&D | 24.1% | 24.8% | -63 bps | 24.5% | -40 bps |

| EBITDA (Before Forex and Other Income and exceptional items) (₹ Cr) | 1,924* | 1,603 | +20.0% | 1,801 | +6.8% |

| EBITDA Margin (%) | 21.0% | 20.4% | +60 bps | 20.3% | +70 bps |

| PBT before share of P/L of JV (₹ Cr) | 1,517 | 1,205 | +25.9% | 1,293 | +17.3% |

| Net Profit for the period (₹ Cr) | 1,032 | 824 | +25.2% | 921 | +12.1% |

*Operating EBITDA excluding one time impact of ₹43 crore on account of derecognition of lease receivable

Additional Financial Highlights:

  • Basic & Diluted EPS stood at ₹17.86 per share
  • Strong net cash position (including investments) stood at $42 million as on June 30, 2026
  • Generated free cash flow of $98 million during the quarter
  • Cash position after payment of Lannett acquisition amounting to $247 million and buyback of $85 million

Operational Performance (Consolidated)

Geographical Revenue Breakdown (₹ Cr):

| Region | Q1FY27 | Q1FY26 | YoY Change | Q4FY26 | QoQ Change |

| USA | 3,770 | 3,488 | +8.1% | 3,543 | +6.4% |

| Europe | 2,937 | 2,338 | +25.6% | 2,795 | +5.1% |

| Growth Markets* | 1,063 | 772 | +37.7% | 980 | +8.5% |

| ARV | 330 | 355 | -6.9% | 328 | +0.8% |

| Total Formulations | 8,101 | 6,953 | +16.5% | 7,646 | +6.0% |

*Includes domestic sales of ₹104 crore in Q1FY27 against ₹75 crore in Q4FY26

API Business Performance (₹ Cr):

| Segment | Q1FY27 | Q1FY26 | YoY Change | Q4FY26 | QoQ Change |

| Beta-lactam | 800 | 636 | +25.7% | 918 | -12.9% |

| Non Beta-lactam | 250 | 279 | -10.6% | 290 | -13.8% |

| Total API | 1,049 | 916 | +14.6% | 1,208 | -13.1% |

Currency Conversions:

  • US revenue: $399 million
  • Europe revenue: €267 million
  • Growth Markets revenue: $113 million
  • ARV revenue: $35 million
  • API revenue: $111 million

Business Segment Performance

US Formulations:

  • Revenue increased by 8.1% YoY to ₹3,770 crore
  • Growth driven by volume gains and new launches, partially offset by no transient product sales
  • Launched 10 products during the quarter
  • Cumulative ANDA filings: 896 with USFDA
  • Final approvals received: 737
  • Tentative approvals: 33

Europe Formulations:

  • Revenue increased by 25.6% YoY to ₹2,937 crore
  • Accounted for 32.1% of consolidated revenue
  • In euro terms, revenue increased by 11.0% YoY to €267 million
  • Robust performance across all key markets

Growth Markets Formulations:

  • Revenue increased by 37.7% YoY to ₹1,063 crore
  • Accounted for 11.6% of consolidated revenue
  • In USD terms, revenue increased by 25.0% YoY to $113 million
  • Strong performance across key markets
  • Domestic sales: ₹104 crore

ARV Formulations:

  • Revenue remained broadly stable at ₹330 crore
  • Accounted for 3.6% of consolidated revenue
  • QoQ variation driven by tender opportunities
  • In USD terms, revenue decreased by 2.5% QoQ to $35 million

Active Pharmaceutical Ingredients (API):

  • Revenue increased 14.6% YoY despite sequential seasonal softness in antibiotics portfolio
  • Contributed 11.5% of consolidated revenue
  • In USD terms, revenue increased by 3.7% YoY to $111 million

Regulatory Approvals

Received final approval for 10 products from USFDA in Q1FY27:

1. Canagliflozin Tablets (FTF) - 100 mg and 300 mg - ANTI-DIABETIC

2. Pirfenidone Capsules (FTF) - 267 mg - ANTIFIBROTIC AGENT

3. Eluxadoline Tablets (FTF) - 75 mg and 100 mg - ANTI-DIARRHEAL

4. Cephalexin for Oral Suspension USP - 125 mg/5 mL and 250 mg/5 mL - ANTI-INFECTIVE

5. Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC) - 30 mg/5 mL - RESPIRATORY DRUGS

6. Icosapent Ethyl Capsules - 1 gram - CARDIO VASCULAR DRUGS

7. Dapagliflozin Tablets (FTF) - 5mg and 10mg - ANTI-DIABETIC (received tentative approval earlier)

8. Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (FTF) - 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg and 10 mg/1000 mg - ANTI-DIABETIC (received tentative approval earlier)

9. Tofacitinib Tablets - 5mg and 10mg - PAIN RELIEF DRUGS (received tentative approval earlier)

10. Glycerol Phenylbutyrate Oral Liquid - 1.1 grams per mL - NITROGEN-BINDING AGENT (received tentative approval earlier)

Management Commentary

Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, commented: "We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders."

Investor Communication

The company will host an earnings call at 8:30 AM IST on August 6, 2026, to discuss the performance and answer questions from participants. Registration link: https://bit.ly/4gVr1CV

Company Background

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The product portfolio spans 7 major therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic.